animals have been so embraced in research. Is this justified? Have they fixed problems with species differences and made animal research more human rel evant? Are there still issues with species differences, and to what extent? Does the new Clustered Regularly Interspaced Short Palindromic Repeats ( CRISPR) technique help? Can GM animals ever provide data sufficiently applicable to humans? If so, what are the ethical costs? How much pain, suffering, and death is involved? 2 What GM Animals Are, How They Are Made, and Problems of Efficiency and Specificity
The genome-an organism's complement of genetic material comprising its entire collection of genes and associated elements-comprises long mole cules of DNA, present in almost all cells. There are many genes along its length, each with a defined function( s ), and serving as a template( s) for the manufac ture of the proteins and enzymes that are the structural and chemical basis of life. The genes themselves are made up of subunits, called nucleotides, the exact sequence of which determines each gene's function. The human genome contains an estimated 20,000 genes and more than three billion nucleotides. Between the genes are other regions of DNA that serve, in various ways, to con trol the expression of those genes, i.e. when the genes are on or off, or to what degree the proteins they produce are synthesized.
Because our genes are fundamental to many normal biological processes, they are also at the root of perturbations of these processes that can cause things to go wrong, resulting in illness and diseases. Genetic studies have, therefore, been pivotal to much biomedical research, attempting to under stand the basis of diseases and what can be done to prevent, treat, and cure them. Because animal approaches increasingly appear to be of poor human relevance, due to the very genetic differences that make species dissimilar and unique, some scientists have modified genes in animals used in experiments to attempt to overcome these differences and make them more relevant to human biology.
Broadly speaking, genes may be inserted or knocked in to animals, their own genes may be deleted or otherwise rendered non-functional or knocked out, or existing genes may be modified or repaired to alter their function. Creating GM animals has undoubtedly become more efficient and specific since their emergence, with the first reports of GM mice in 1974 (Jaenisch and Mintz, 1974) . Much of what is involved is technical in nature, so it will not be discussed in detail here; suffice to say that various methods are avail able to introduce the DNA of interest-the DNA, synthesized in the laboratory, which will induce the desired genetic modification-into the zygotes (fertil ized eggs) or emb ry os of the animals to be modified. Briefly, it may be injected into fertilized eggs (pronuclear microinjection) or into emb ry onic stem cells (Escs or ES cells)-cells in a developing emb ry o with the capacity to become one of many different, specialized types of cell-that are removed from an emb ry o for manipulation and, subsequently, re-injected into developing em b ry os. These are subsequently surgically implanted into surrogate mothers, in which the emb ry os will develop, as intended, to term and result in live births is specifically designed to seek and bind to precise targets in the genome that are to be modified; and an associated enzyme, Casg, which cuts the DNA at the target site and initiates the genetic modification process. Put simply, CRISPR causes complete (double-stranded) breaks in the DNA at (in theo ry ) specific targeted sites, which are subsequently repaired by the cell's own DNA-repair systems.
However, the repair process is inherently error prone and generates small insertions or deletions of DNA at the break sites, which can be used to disrupt gene function or, in the presence of engineered DNA molecules introduced ex perimentally, to alter the DNA specifically at that site. While this method is generally considered to be much more efficient and specific compared to other approaches, any accurate, definitive, quantitative estimation of the efficiency of CRISPR is difficult to find, as estimates va ry considerably and are affected by many factors, including the nature of the target site and the CRISPR molecule used. Generally, the method has improved over time, but there is a strong argu ment that CRISPR remains far from good enough, scientifically and ethically. One 2017 review reported that "knock-in efficiencies are still low and highly variable," with different genetic loci in zebrafish emb ry os having genes suc cessfully knocked in, in 45°/o and 70% of cases, though only in 1. 7% and 3.5% respectively, with any real precision. Associated successful germline modifica tions to produce founder fish for breeding occurred on average just 3.8% of the time (Albadri, Del Bene and Revenu, 2017, p. 8) . Another recent study found an average of 9.2% of transferred emb ry os resulted in mouse pups, and an av erage of 76% of these had been successfully knocked out for a specific gene. The generation of pups harboring specific point mutations was lower: 6.5% of transferred emb ry os produced pups, though less than 8% of these had the desired mutation (Nakagawa et al., 2016) . In cell lines, mutation efficiencies are generally higher, though they range from lower than 5% up to 90%, and gene knock in less than 10% up to 66% (see Bortesi et al., 2016) .
Regardless of on-target efficiency, one issue has plagued the creation of GM animals: off-target effects, or mutations induced by the GM process that are not intended but affect other non-specific sites in the genome (Fu et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013) . This is a significant scientific and wel fare issue, which raises serious concerns over the wider application of genetic modification in science, medicine, and agriculture (Kanchiswamy et al., 2016; Kleinstiver et al., 2016) . These concerns include: the low birth rates of animals with the desired genetic modification and the associated high "wastage", or animals that may suffer and/ or be killed as a result; and many animals who harbor off-target mutations adversely affecting the animal's characteristics (phenotype) ( Guha, Wai and Hausner, 2017 and mutation results in toxicity to those cells in which it occurs , and their repair causes chromosomal rearrangements, which can acti vate genes that can cause cancer  see also Cho et al., 2014) . Not surprisingly, "major concerns of off-target mutations have been observed in medical and clinical studies," as well (Kanchiswamy et al., 2016, p. 564) . This leads to difficulty in interpreting data but may also cause these animals further pain and suffering, due to the off-target effects, and death as they succumb to adverse off-target effects or are killed because they are of no experimental use. Despite the considerable effort put into improving the situation, the ex tent of off-target effects is still a matter of serious debate (Bassett, 2017) . Astoundingly, they are thought to be up to 50% more common than the desired on-target mutation efficiency, and they may occur at sites quite differ ent to the target site, both of which are of serious concern (Fu et al., 2013; see also Bortesi et al., 2016; Komor, Badran and Liu, 2017) . Many computational approaches to assessing potential CRISPR off-target problems exist. Though useful, each is biased regarding the type of off-target sites it may or may not fail to predict. It is therefore widely accepted that other, unbiased methods of assessment must be used to help avoid missing off-target effects that may be seen experimentally ( see Bolukbasi, Gupta and Wolfe, 2016; D'Agostino and D'Aniello, 2017; Tsai et al., 2015) . Some CRIS PR experiments show more than 100 off-target mutations, while others appear to show none (Bolukbasi et al., 2016) . Some analyses have suggested little or no off-target activity for some CRISPR molecules, though these analyses examined preselected genomic sites only so are likely to suffer from bias (see Bortesi et al., 2016) . Any single technique will miss off-target sites that others will detect; and, unfortunately, the most comprehensive method-whole genome sequencing-is technically difficult and expensive. For example, a rare mutation ( 0.1% frequency) would require sequencing 1,500 genomes to give a 95% probability of finding this mutation at least once (Sluch et al., 2015) .
A recent ( 2017) study attempted to complete a comprehensive whole-genome analysis to determine the actual prevalence of all off-target mutations in a CRISPR-edited mouse, not only the larger mutations, such as insertions and deletions ( ind els) of DNA but also the smaller, though no less important, single nucleotide variants ( SNVs) that are often not sought. Schaefer and colleagues, reported "an unexpectedly high number of SNVs;' in addition to an average of 146 indels, with many of these in known genes (Schaefer et al., 2017, p. 547) . The authors concluded that "concerns persist" over the unpredictable nature of CRISPR off-target mutation sites, which were likely to have a detrimental impact on key cellular processes and would likely manifest in adverse phe notypes. This specific issue remains, however, highly controversial. In March 2018 1 Schaefer and colleagues retracted their paper-in the face of pressure from some members of the scientific community working on CRISPR-on the grounds that the study results were irreproducible and unsupported by the data, and the study lacked key controls (Editorial, 2018; Schaefer et al., 2018) . Retraction of this paper does not, of course, remotely prove or even suggest that CRIS PR is sufficiently free of off-target effects to be safely used in humans. Most stakeholders who have opined in its wake have urged further progressive, yet cautious, research to elucidate the situation and stopped short of inferring an all clear from the authors' most recent work (Schaefer et al, 2018) . With particular regard to their revision, Schaefer et al. are careful to note ( correctly) that their latest data suggest that, "in specific cases, CRISPR [ ... ]m ay not intro duce numerous, off-target mutations" (Abstract). Others note that this simply means that the concern over off-target effects 'Just isn't perhaps as big as that initial study suggested." (Brown, 2018) . More generally, all involved appear to accept that far too little data exist to reach any robust, definitive conclu sions about off-target effects associated with CRISPR, either way. This sensible, evidence-based view is supported by the many studies that exist, with a full spectrum of results ( such as those referenced in this chapter), that serve only to rubber stamp the view that this field is young, and the question of off-target effects is still completely wide open.
Crucially, just before this Volume went to press, this caution was further jus tified by a detailed study published in Nature Biotechnology, which showed that the specificity of CRISPR-induced genetic alternations had been over estimated to date, due to exploration of them being "limited to the immediate vicinity of the target site and distal off-target sequences" (Kosicki et al., 2018) . The authors' more thorough and detailed investigations revealed that-in two different types of mouse cells and a differentiated human cell-line alike-mu tagenesis at the target sites was often much more significant than intended/ expected. Instead of the aforementioned small insertions or deletions of DNA, the resulting CRISPR-mediated genetic alterations were frequently "large dele tions and more complex genomic rearrangements': often extending to many kilobases. Further, off-target lesions often resulted in "genomic damage", which "may have pathogenic consequences." The important warnings of their con clusions bear repeating here: extensive on-target genomic damage is a com mon outcome; consequences are not limited to the target locus but will affect more distal genes; some repercussions may initiate neoplasia ( cancer); it is likely that some cells in each protocol would contain important pathogenic lesions, some of which would become cancer-causing in time; and others. Such frequent and extensive genetic damage is and has been undetectable by the means often used to identify it, leading to its under-reporting and under-appreciation, and so much more comprehensive analysis of the genetic Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access consequences of CRISPR experiments is warranted and necessary. This may be of urgent concern due to the fact that six clinical trials of CRIS PR are currently underway, for various malignancies/cancers, including esophageal, nasopha ryngeal, gastric, non-small cell lung cancer, leukemias/lymphomas and other hematological malignancies (see Clinicaltrials.gov). Clearly, off-target mutations remain a major issue, with persistent targeting of unintended genomic loci (Bisaria,Jarmoskaite and Herschlag, 2017, p. 21 ; see also Tsai and Joung, 2016) , even as steps are taken to mitigate their occurrence and effects, such as using engineered/modified CRISPR components (see e.g. Bayat et al., 2017; Chandrasekaran, Song and Ramakrishna, 2017; Combes and Balls, 2014; Ding et al., 2016; Guha, Wai and Hausner, 2017) . It is widely believed that the factors controlling CRISPR's precision and accuracy "are still not ful ly understood," and obstacles remain on the path to any clinical application (Jiang and Doudna, 2017, p. 524) . "Much remains to be learned regarding the efficiency and specificity of CRISPR/Cas9-mediated gene editing in human cells, especially in emb ry os." (Liang et al., 2015, p. 364 ) It is considered "nec essa ry " to develop methods of detecting off-target mutations that are much more sensitive (Tsai and Joung, 2016, p. 310 ) ; but it is also thought that these will never be removed completely (Bassett, 2017 ) , and that off-target effects will still occur often, no matter how high the on-target specificity (Liang et al., 2015) . Off-target mutations remain stubbornly numerous and confounding in spite of many, multi-faceted efforts to reduce them and their impact; and this may have serious consequences for the use of CRIS PR, even in laboratory based research, where there will be more acceptance of them. This means that the role of off-target effects in any observations cannot be ruled out, but espe cially in clinical settings, where safety is paramount and even off-target muta tion frequencies as low as 0.1% can have serious consequences .
Finally, shortly before this Volume went to press, yet another, but differ ent, clarion call for great caution came in the form of two papers published in Nature (Ih ry et al., 2018; Haapaniemi et al., 2018) . The double-strand DNA breaks created by CRISPR/Cas9 as part of its mechanism of action activate a gene called p53, which is known as the "guardian of the genome"-involved in the repair of DNA damage and, if that damage is sufficiently significant, in apoptosis, or the destruction of the cell containing the damaged DNA. It is because of these functions that p53-a tumor suppressor gene-is known to be mutated in more than half of all human cancers (Hollstein et al., 1991; Fo ronda and Dow, 2018) ; if p53 cannot carry out its normal activities, damaged cells may go on to become tumorous (Ferrarelli, 2018) . This is an issue because, as one might expect, p53 blocks CRISPR/Cas9 activity; and it therefore follows that cells that are experimentally modified by CRISPR, must, thus, tolerate DNA damage, and so must have deficient p53. In selecting for CRISPR-modified cells, therefore, one may be selecting for cells that could lead to tumor forma tion, which could be clinically catastrophic. As one of the authors opined, "By picking cells that have successfully repaired the damaged gene we intended to fix, we might inadvertently also pick cells without functional p53. If transplant ed into a patient, as in gene therapy for inherited diseases, such cells could give rise to cancer, raising concerns for the safety of CRIS PR-based gene therapies." (Karolinska Institutet, 2018) .
It has been suggested that such cells could be identified and eliminated by in vitro screening (Foronda and Dow, 2018) , but various problems remain. Just one, single DNA break seems to be sufficient to prime p53 activity, and lead to cell arrest or death (Foronda and Dow, 2018; Ih ry et al., 2018) , so the problem m ay be greater than first thought. Some have inferred or implied that this is a new discovery, but it is not: almost quarter of a centu ry ago, this was demon strated in human fibroblasts (Di Leonardo et al., 1994) . Further, CRISPR-editing issues were reported in 2016 with some types of cells, including prima ry and stem cells (Hockemeyer and Jaenisch, 2016; Carroll, 2018) , the latter being the type of cell involved in one of the recent Nature papers (Ih ry et al., 2018)-so this m ay be another illustration of lack of caution among some CRISPR re searchers and advocates, and further reason to doubt that due caution and critical approach are being applied widely enough-particularly as the under lying mechanism was not pursued (Carroll, 2018) . As stated in a recent, highly relevant review, "It is surprising that this phenomenon was not recognized much earlier." (Carroll, 2018) . Because break-induced toxicity has not been de tected in all cell types, but also due to it not being seen in some cell types that do have functional p53, it means that "the induced arrest phenomenon will have to be tested and addressed for each type of target cell" as "that pathw ay is not the whole sto ry " (Carroll, 2018). Finally, while selection is possible in vitro, it is not an option for in vivo somatic gene correction, in which this would have serious consequences for animals and humans (Foronda and Dow, 2018) .
3
Current and Intended Uses of GM Animals
.1
Biomedical Many GM animals are used in basic research with no direct application ( for example, to a particular therapy for a specific disease), but with aims to investi gate the functions of particular genes, for example, and the nature of their reg ulation. Others are used as specific models for many different human diseases, including multiple infectious diseases, such as HIV, immune system defects, blood and metabolic disorders, muscular dystrophy, cancer immunotherapies, among others (Comu, Mussolino and Cathomen, 2017) . Gene therapy inter ventions for some of these diseases have already reached clinical trials, such as HIV/AIDS therapies (Comu, Mussolino and Cathomen, 2017) ; though there are some serious concerns over potential immune reactions in humans to two of the most common proteins used in the CRISPR/Casg system. Recent analysis of human blood samples revealed the presence of antibodies to Casg proteins in 65%-79°/o of individuals; and around half of all the blood samples harbored immune cells with the potential to destroy human cells, containing one of the Casg proteins ( Charlesworth et al., 2018) . The potential severity of any immune reaction in patients is unknown, but it could range from making CRISPR non functional, to dangerous inflammatory reactions.
Efforts are being made to use c RI s PR to deactivate and render some viruses non-infectious and/or non-pathogenic, such as hepatitis B and C viruses and HIV (Doerflinger et al., 2017; Huang et al., 2017; Li et al., 2017; Moyo et al., 2017; Soppe and Lebbink, 2017) . Serious caution has been advised, however, due to the risk of causing mutations that increase, rather than decrease, viru lence . It is claimed that CRISPR holds the k ey to translating data from rodent models of psychiatric disorders and neurobehavioral traits to humans, including disorders associated with anxiety, mood, and substance and impulse-control (Baud and Flint, 2017, p. 373 ). CRISPR's potential for can cer biology has been expounded, as it can recreate potential cancer-causing mutations identified in human tumors, in both cell lines and GM animals (Guemet and Grumolato, 2017) . Some GM animals are used in attempts to pro duce medically important proteins, for example, in cows' milk, which can be generated in high volumes and purified from the milk for clinical use. Examples include treatments for some blood disorders, osteoporosis, and emphysema (Moura, Melo and de Figueiredo Freitas, 2011) . GM animals are central to efforts to use animals as a source of organs for human transplantation (xeno transplantation), targeting biological pathways involved in immune rejection of transplanted organs.
.2
Fa nn/Fo od Animals A major application of GM technology (GM also can mean genetic modification or manipulation, as well as genetically modified) is the engineering of animals used for food (Ledford, 2015) . Examples include, chickens producing only fe male offspring for egg-laying, cows producing only male offspring for better meat yield, pigs who can be fattened with less food, cashmere goats producing more meat from greater muscle mass and longer hair for greater wool yield; and efforts to facilitate greater stocking density, such as cattle without horns and animals with greater resistance to disease ( see Frewer et al., 2013; Nuffield Council on Bioethics, 2016) . Double-muscled pigs (Cyranoski, 2015) , rabbits (Lv et al., 2016) , sheep and cows (Proudfoot et al., 2015; Luo et al., 2014) have been created for human consumption, though many died early and were unhealthy, and birthing difficulties occurred due to their size ( Cyranoski, 2015) . Cows with out horns can be housed more densely with lower risk of goring injuries (Loria K, 2016; Carlson et al., 2016) . While there may be welfare benefits-millions of cattle would no longer need to be dehorned, which can be very painful they would be farmed more intensively and have less space to live in, further compromising their welfare. Other efforts include cows that produce milk that does not induce allergies in humans (Yu et al., 2011) ; milk with altered fatty acid content, and milk that contains high levels of lactoferrin (Yang et al., 2008a) ; cows who produce "tastier beef" because their flesh contains more fat ( Guo et al., 2017 ) ; and pigs who bleed out more efficiently at slaughter (Hai et al., 2014) and have omega-3 fatty acids in their flesh (Lai et al., 2006) . GM salmon, modi fied so that they grow at twice the rate of normal salmon and can be housed in tanks on land, have been approved for human consumption in the United States (us) (Connor, 2015) . Much of this is undoubtedly the result of lobbying by vested interests that stand to profit from these projects, who assert that, for instance, the Earth's growing population and shifting appetites will necessitate considerable increases in food production that cannot be achieved by any other means alone; yet, there is strong counter evidence and opinion that alterna tive strategies could meet that need, such as reducing food wastage; changing consumer demand and preferences for meat, dairy, and eggs; and improving farming and production methods by other means (High Level Panel of Experts on Food Security and Nutrition, 2014). Despite the potential for both direct and indirect effects on animal welfare in this area, it is acknowledged that too little attention has been devoted to the genetic modification of "farm animals" and to the regulation of the practice (Nuffield Council on Bioethics, 2016).
However, the creation of GM animals commonly used for food is not lim ited to making them easier to manage or more profitable for their meat and milk. Pigs are touted as being more appropriate models of human diseases than mice, for example, for cystic fibrosis, cancer, diabetes, neurological disor ders, high cholesterol, and muscular dystrophy; while a gene associated with achondroplasia has been targeted in cattle ( Carlson et al., 2012; Petersen and Niemann, 2015) .
3.3
Do g s and Monkeys Concerns that less strict regulations in countries outside of the Eu and the us may lead to GM projects that may not be approved elsewhere appear to (Hong et al., 2009 ). This was far from efficient. 344 emb ry os transferred to 20 surrogate mother dogs, resulted in seven pregnan cies and six live births. More recently, another Chinese laborato ry created GM dogs using CRISPR, knocking out a gene controlling muscle growth, resulting in dogs who were "much more muscular" (Doane, 2016; Zou et al., 2015) . Their work was defended via a tenuous link to the creation of future dogs who could model, for example, Parkinson's disease; but only two of 60 edited emb ry os were "successful:' Elsewhere in China, GM monkeys have been created with apparently similar characteristics to autism. Eight macaques ( out of "dozens" of GM emb ry os) were born with a gene (M ECP2) linked to autism in humans, who showed signs such as running "obsessively in circles", ignoring their peers, and grunting anxiously when stared at ( Cyranoski, 2016b; Liu et al., 2016; Snow don, 2016) . Interestingly, when espousing the use of "large animals" as GM models for human diseases, those who may otherwise stoutly defend GM mice are open to criticizing them. For example, one recent paper, authored by scientists creating GM livestock, noted that "the drawbacks of using rodents to model humans are well established [ ... ] mice make poor models for reproductive physiology, pulmona ry problems, metabolic regulation, and many other fields of inqui ry " (West and Gill, 2016) . Unfortunately for such advocates, as discussed in this chapter and in works referenced in it, it appears that "larger animals", GM or not, remain poor models for these areas and more, and can only ever be so. This is compounded by the same, or even greater, confounding issues of low efficiency and a variety of limitations and complications ( see section on non human primates, NHPs, below).
Suffering, We lfare, and Ethical Issues with GM Animals
Many animal researchers acknowledge that creating GM animals involves suf fering at eve ry step, from generating sufficient eggs to emb ry os for modification, through to the pain and suffering experienced by many progeny (Laborato ry Animal Science Association, 2008; Robinson, Jennings and Working, 2004) .
4.1

Breeding and the GM Process
Producing eggs for the emb ry os used in the GM process involves drug-induced superovulation of females, whose fertilized eggs are collected post-mating, which may involve killing the females, a common practice in rodents, or at least surge ry under general anesthesia ( more "valuable" species). Approved killing methods for rodents are, commonly, neck dislocation or carbon dioxide suffocation, which can both (not surprisingly) cause distress (Robinson et al., 2004) . Both superovulation and fertilized-egg collection can cause discom fort, stress, and post-operative pain (Camara, et al., 2008) . After modification, emb ry os are implanted into surrogate mothers in the form of pseudopregnant females, who have been previously mated with vasectomized males (The Boyd Group, 1999) . Pre-and post-natal death of offspring may be significant. One report showed that an average of just 29% of implanted emb ry os survived to weaning, and only a quarter of these (7°/o of implanted emb ry os) (Hubrecht, 1995) , or an average of 15% ( Robinson et al., 2004) , may be GM. Miscarriages may cause pain and distress, and such poor efficiency means that many donor and recipient animals must be used to produce a relatively small number of desired GM individuals. Genotyping of resultant offspring may involve blood sampling or tissue biopsy. Invasive methods are still common, including tail snipping, ear snipping/punching, or even toe amputation, all causing pain in mice (Robinson et al., 2004) . The genetic modification process has been documented, at least in larger animals, such as sheep and cattle, as a factor in increased gestation length, greater body weight, risk of dystocia ( difficult birth), and various perinatal anomalies and loss. In mice, there is also evidence of increased emb ry onic and fetal loss ( Camar et al., 2008) .
4.2
Animal Lives Wa sted The persistent inefficiency of the GM process is a serious welfare issue (Boyd Group, 1999; Camara et al., 2008 ; Laborato ry Animal Science Association, 2008; Robinson et al., 2004) . It is difficult to quantify, as many countries do not re quire the reporting of GM-animal statistics (Taylor et al., 2008) . In the UK, sta tistics indicate a high degree of wastage ( around 50% of a total of more than 4 million animal procedures in 2015, involved the creation and breeding of GM animals not used in subsequent experiments), and specific GM license appli cations are revealing: seven projects from 2014-2015 proposed using a total of almost 27,000 animals ( UK Home Office, 2014).
4.3
Effe cts of Genetic Modification Inserted genetic material may have adverse effects on GM emb ry os/animals. Some may be unpredictable, such the aforementioned off-target effects; while others are expected and the result of on-target effects, such as GM mice who will develop painful cancers. Naturally, the GM process may not necessarily adversely impact welfare; but the critical point is that, frequently, the welfare consequences of the GM process cannot be predicted in detail, nor can they be assessed properly. Welfare assessments are by their nature wide open to subjectivity and opinion, and much more research needs to be done in this Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access area to increase objectivity, if indeed this is possible to any significant degree (Hawkins et al., 2011 , Wells et al., 2006 . Therefore, it is acknowledged that reduced viability or impaired health may be expected (Bundesamt fiir Veter inarwesen, 2006); while some estimates suggest around 20% of GM animals suffer minor discomfo rt, 15% severe discomfo rt, and 30% increases in mortality and susceptibility to disease (Thon et al., 2002 ) . Indications may include, for instance, developmental abnormalities, such as cleft palate; perinatal and post-weaning mortality; skeletal abnormalities, in cluding malformed limbs; discharge from eyes and ears; diarrhea; poor posture, gait, and ataxia; stereotypies, such as lack of alertness, poor or over-grooming, circling in cage; absence of teeth; poor mothering; poor thermoregulatory ability; enhanced growth of tumors and development of metastases, often at atypical sites; increased aggression; seizures; a range of diseases, including dia betes, osteoporosis, degenerative joint disease, inflammatory bowel disease, and ulcerative colitis; sensory and locomotor abnormalities affecting sight, hearing, smell, balance, and social interactions; and increased incidence of infectious disease (Dennis, 2002 ) . GM mice databases reveal progressive hear ing loss and deafness; development of diabetes; impaired movement and coordination, including tremors and involuntary movements, difficulty in ini tiating movement, abnormal posture, and paralysis; susceptibility to infectious disease; colitis; progressive muscle weakness; kidney inflammation; premature death; intestinal obstruction; respiratory distress; h yp eractivity; heart failure; internal bleeding/brain hemorrhage; self-harm; seizures; vision problems and blindness; and ma ny more (e.g., Mouse ENCODE Consortium, mouseencode. org; Mouse Genome Informatics, MGI, database, informatics.jax.org). The Mouse Genome Informatics (MG I) database lists mice under the following cat egories ( among others): with abnormality of blood, connective tissue, head or neck, limbs, metabolism, prenatal development/birth, cardiovascular system, digestive system, ear, eye, genitourinary system, immune system, musculature, nervous system, respiratory system, skeletal system, and cancers. The scale of this must also be mentioned: as of July 2017, the MGI database cites 51,000 mutant alleles in mice, with more than 3,100 human disease models; the Inter national Mouse Strain Resource ( findmice.org) lists around 40,000 strains as available worldwide; the International Knockout Mouse Consortium has gen erated around 5,000 mutant mouse lines (Rosen, Schick and Wurst, 2015) ; and the International Mouse Phenotyping Consortium intends to generate 20,000 knockout mouse strains (mousephenotype.org) (Kosciel ny et al., 2014).
Off-target modifications may induce mutations that abrogate gene function and/or cause rearrangements of the genome with other, subsequent muta tional effects on other genes. In assessing effects of GM on welfare, it has been cautioned that setting a "normal" baseline must be done carefully. For example, it is normal for GM mice engineered to have vestibular abnormalities to spend much time circling in their cages. This may be normal for these mice but should not be considered normal from a welfare perspective (Hawkins et al., 2011) .
4-4
In creasing Nu mbers of GM Animals Many of these welfare issues are not exclusive to CRISPR and exist for other GM methods. It has been argued that CRISPR should mitigate many of these, with its simplicity and greater efficiency, and so should be welcomed by ani mal advocates. To some extent this may be true, in time. However, the corol lary gives great cause for concern, that this simplicity and efficiency will also "not only increase in the range and diversity of transgenic rodent strains but will greatly expedite transgenesis in other species, including non-human pri mates" (Combes and Balls, 2014, p. 137) . In this regard, CRISPR is described as a mixed blessing (Hendriksen and Spielmann, 2014) ; and animal ethicist Bernard Rollin (2015) accepts that easier GM techniques would undoubtedly lead to an increase in the number of animals used "as more researchers engage in hither to impossible animal research". It has been said that CRISPR will revolutionize mouse genetics by reducing the time it takes to create a new GM model from years to months, or even weeks (Fellmann et al., 2017 ) . In other words, for any reduction and refinement in any specific GM experiment due to CRISPR, a greater overall number of GM experiments will offset this, compounded by more experiments on a wider range of species, including dogs and monkeys. This is not mere speculation. Aside from being logical, and in addition to multi-stakeholder enthusiasm for CRISPR and associated market projections, it is clear from current scientific literature. Many speculative claims for CRISPR reflect an excitement that, in part, is responsible for the great expansion of interest in the technology and in the creation of greater numbers of GM ani mals in academe, biotech firms, and large pharmaceutical companies ( Cor nu et al., 2017) . For example, it is estimated that by 2021, the GM market will be worth US$6.28 billion (MarketsandMarkets, 2017). It has, therefore, been strongly suggested that the welfare consequences of genetic modification for all species should be monitored and explored in greater detail. Perhaps, at least, an in-depth, systematic, critical assessment of the rationale for using GM animals in human disease research is warranted; and proj ects involving GM animals should be approved only in "extremely exceptional circumstances" (Combes and Balls, 2014, p. 143 ; see also Mepham et al., 1998) . Unfortunately, interest in CRISPR is, at least for now, manifesting in substantial animal use. The scientific literature shows (as of June 2017) more than 6 1 000 publications, up from fewer than 4,000 just a year earlier (June 2016), and just over 600, 18 months prior to that (Nuffield Council on Bioethics, 2016).
In creasing Nu mbers of No n-Human Prim ates (NHPs)
There is, therefore, great, well-founded, concern that this interest will trans late into greater creation of GM monkeys (e.g. Liu et al., 2014; Niu et al., 2014) . Examples of GM primates have already been mentioned ( Cyranoski, 2016b; Liu et al., 2016; Sasaki et al., 2009; Snowdon, 2016) , following on from, for ex ample, the first reports of GM macaques in 2001 (Chan et al., 2001 , and a GM NHP model of Huntington's disease (Yang et al., 2008b ) . Some scientists are calling for further increases. To illustrate, a 2016 paper lamenting the failure of animal research (including NHPs) to translate to a greater understanding of human brain disorders and their treatment-largely due to "lack of good animal models" and "profound differences in brain and behavior" between humans and nonhumans-puts its weight firmly, and speculatively, behind GM NHPs as a solution (Jennings et al., 2016 (Jennings et al., , p. 1123 . Associated suffering is justified by a brief assurance of veterinary oversight and intervention. While accepting that greatly expanding GM NHP creation and use is challenging in many ways, the authors propose a "concerted international effort" to over come those challenges (Jennings et al., 2016 (Jennings et al., , p. 1128 , involving automated methods for training the animals to comply with the researchers' demands, chronic use of intracranial electrodes, and the creation of an international network of NHP centers and vendors. Overall, a horrifying vision for animal advocates, and scientifically unjustifiable in any case. My colleagues ( at Cru elty Free International, and indeed in the wider animal protection commu nity) and I agree that there is a "dismal record of drug development for neuro logical and psychiatric disease over the past several decades" and that "basic neuroscience has failed to deliver substantially new and effective treatments for many brain disorders, partially because the animal modelling was done in species whose brains are too dissimilar from those of humans" (Jennings et al., 2016 (Jennings et al., , p. 1128 . However, we believe that modifying a gene or two in these poor models cannot overcome these problems or lead to research that is any less unethical.
GM NHP creation also suffers from the same problems as GM rodents, even 16 years after the first GM monkey was born (Chan et al., 2001) ; and so, wide spread, efficient, successful, generation of human-relevant GM NHPs may be a forlorn hope anyway (Luo, Li and Su, 2016) . Surprisingly little analysis had been done of this until recently. Though CRISPR has intensified the genera tion of GM NHPs, targeting efficiency in NHPs is still low, "successful gene replacement in monkeys via the CRIPSR/Casg system remains elusive, possibly due to the complexity of DNA repair mechanisms in monkeys" (Luo et al., 2016, p. 242) , and "there are still some technical limitations for its use in non-human primates" . A 2017 report acknowledges "the incidence of undesirable outcomes has not been well characterized". It states: "Most studies experienced ve ry high rates of developmental arrest ( can be go%) ... [which] further raises concerns about non-genetic technical factors contributing to low rates of survival" (Midic et al., 2017, p. 4) . While this study claimed that the cre ation of GM NHP emb ry os could be 80%-100% efficient, this does not reflect on the efficiency of generating otherwise healthy adult NHPs with desired genetic modifications, and without confounding and/or welfare-compromising off target effects. The same study suggests that mosaicism (where offspring con tain cells with different genes/gene variants) is "substantial" and is "a significant limitation," and accepts that the creation of GM NHPs to date was "achieved at a ve ry high cost in terms of the number of emb ry os used," due in part to the "ve ry limited ( around 10%) viability of transferred emb ry os to term" (Midic et al., 2017, p. 15 ; see also Chen et al., 2015) . They conclude that inefficiency remains "a major barrier to practical use of the technology in nonhuman pri mates" (Midic et al., 2017, p. 15) ; and that the entire process is financially costly. To illustrate, one effort to generate GM NHPs via CRISPR, with two disrupted genes, reported that of 22 emb ry os injected, 15 ( 68%) survived culturing, while on average just over one third of these contained the desired modification . Subsequent attempts to generate GM monkeys involved injecting 186 zygotes; 83 ( 45°/o) were transferred to 29 surrogate females, establishing 10 pregnancies (34°/o ), with 19 fetuses. The paper was published while 8/10 were still pregnant; one miscarried, and the other gave birth to twins, whose genes had been successfully modified, though mosaicism was confirmed, and pheno type had yet to be established. This is all of particular concern because experimentation on monkeys is opposed much more strongly than on rodents ( Aldhous, Coghlan and Copley, 1999; Animal Aid, 2003; Clemence and Leaman, 2016; Leaman, Latter and Clem ence, 2014; TNS Opinion & Social, 2010 ) ; and genetic manipulation of "higher" organisms evokes stronger concern from the public ( Olsson and Sand0e, 2010 ) . The European Science Foundation's European Medical Research Councils group has stated: "Whether a species needs special protection should not be based solely on its phylogenetic relations to humans, but on its potential for suffering. NHPs are distinguished by the ve ry advanced nature of their social, cognitive, sensory, and motor functions" (Olsson and Sand0e, 2010, p. 185) .
Fa ilure of GM Animals and Consequences for Animals and Humans
Much has been published on the failures of GM animals to live up to their prom ise, though criticisms of GM animals are frequently understated, couched, for example, as follows: th ey do not alw ay s accurately reflect the human condition; (Pratt et al., 2012 ) , multiple sclerosis, cancers, and immunothera py (Ruggeri, Camp and Miknyoczki, 2014) , migraine (Storer, Supronsinchai and Srikiatkhachom, 2015) , pain ( Craig, 2009; Mogil, 2009 ) , and depression (Benatar, 2007; Bhogal and Combes, 2006; Davis, 2008; McGonigle, 2014; Norgren, 2004; Webb, 2014) . It is, however, increasingly acknowledged in scientific literature that GM animals are failing to deliver by any measure. For example, GM-based "advances" in animal models of many human conditions and diseases "have not made a significant increase in improving the rate of success in Phase II proof of-concept studies"; in other words, GM animals are not leading to more, bet ter, safer drugs and indeed m ay well be hindering the process because they are misleading (Hunter, 2011, p. 1) . GM-animal models of CNS disorders "have been increasingly criticized in the wake of numerous clinical trial failures of NCEs [ new chemical entities, or new drugs] with promising preclinical profiles" (McGonigle, 2014, p. 140 ), and they are "criticized for their limited ability to pre dict NCE efficacy, safety and toxicity in humans" (McGonigle and Ruggeri, 2014, p. 162 ) . Clinical trials of gene therapy for heart failure and muscular dystrophy, despite early promise, have failed (Hulot, Ishikawa and Haj jar, 2016; Lu, Cirak and Partridge, 2014 ) . And despite many years of substantial effort in the field of xenotransplantation, and early promises that successful transplantation of pig organs into humans would be realized by 2010 and worth multiple billions of dollars, the most recent developments claim no more success than a GM pig's heart surviving in a monkey for 51 d ay s (Johnston, 2016) , or in the abdomen of a baboon in addition to its own heart for just over two years, until they were re jected when immunosuppressive drugs were reduced (Mohiuddin et al., 2016; Servick, 2016) . Attempts to overcome other significant hurdles continue, such as porcine endogenous retrovirus (PERV) in pigs, which can cause problems in humans ; but there remain persistent issues, such as immune rejec tion; transmission of infectious agents; ethical problems and boundaries; as pects of physiological compatibility, such as discrepancies in coagulation and metabolism; and others (Niemann and Petersen, 2016) . Some argue xenotrans plantation is not needed anyway. Prevention of much of the need for trans plantation via education and health measures, improved donor recruitment, and mandated choice and presumed consent/opt-out schemes, and others have all had positive outcomes in countries that have adopted them (Perera, Mirza and Elias, 2009 With specific regard to CRISPR, there is also evidence to question claims that it can improve matters and facilitate more accurate and human-relevant models. An approach utilizing Mo rp holino oli g omers (Mos) has been widely used to investigate gene function in zebrafish, but attempts to confirm findings for specific genes using CRISPR have been extremely confounding. One study reported that most genes altered by CRIS PR failed to show similar phenotypes to experiments that altered the expression of the same genes using Mos, which the authors attributed to differing off-target effects from the techniques (Kok et al., 2015) . This is mirrored in a study comparing selected genes affected by CRISPR and a gene-silencing method using short hairpin RN As (shRNA). These methods were found to have similar precision; but each affected "numerous" genes that the other did not, attributable to differences in off-target effects and in the timing of each (Morgens et al., 2016) . To illustrate, a recent study revealed that previous research implicating the MELK gene in certain breast cancers-with sufficient certainty to prompt pharmaceutical companies to develop drugs to block its activity, some of which proceeded to human trials may be unreliable. When the MELK gene was knocked out using CRISPR, can cer cells multiplied unexpectedly, and drugs that targeted MELK still stopped their growth. This casts doubt on the role of MELK, and suggests that drugs targeting MELK work through other targets .
It is often, perfectly reasonably, asked if such failures may be balanced against any successes of GM technology. This is not the purpose of this chapter, which is to highlight issues and caveats with it and to supply a more critical ar gument against its use. However, any claimed successes, in which it is implied that the use of GM animals has resulted directly in human benefit, must fulfil the following criteria: data from the GM animal experiments must be reliably and sufficiently translatable to humans; these experiments must have provid ed data that could not have been obtained in any other way; and these data must have been critical to the ultimate human benefit. Even if, for the sake of argument, one assumes such examples exist, they still must be balanced against an objective appraisal of the scale of failure and against the ethical cost of the animal research involved.
Reasons for These Failures
Reasons proffered for this scale of failure include the evolutionary distance of humans and non-human species-approximately 65 million years for humans and mice-and all consequent differences in gene complement and expression, the artificiality of induced diseases, and the inbred strains of Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access animals often used (Davis, 2008) . See also two comprehensive reviews of ge netic differences between humans and chimpanzees ( chimpanzees were used in science in the us until very recently), and humans and monkeys (Bailey, 2011 (Bailey, , 2014 . Even with current knowledge, limited because such differences have barely been sought, they are much more widespread and extensive, with significant and varied consequences, than is generally accepted. There are sig nificant differences in gene complement, but more importantly, in gene ex pression, i.e., how these genes are regulated and used in the organism, even where they are common to both species. These differences affect all biologi cal systems, but notably the immune system, the brain, and the liver, which are fundamental to much biomedical research involving infectious agents and disease, autoimmunity and inflammation, neuroscience and neurological dis eases, and drug safety and efficacy. It is these differences that underpin the failures of animal research, whether GM or not, discussed in this chapter. Of course, genetic differences between humans and NHPs, as appreciable as they are, are not as great as those between humans and mice, who constitute the greatest numbers of GM animals used in science. These differences have not yet been elucidated in detail, but illustrative examples exist. For example, a systematic comparison of the mouse and human genomes has revealed that there is significant conservation of functional genes themselves, with around half of human DNA aligning with mouse DNA when directly compared; how ever, this of course means that half of it does not. Furthermore, there are, crucially, "wide ranging differences" in many biological pathw ay s and cellular functions, which show "considerable divergence"; and the areas of the genome that control and regulate gene expression are substantially different (Yue et al., 2014, p. 355) . Indeed, many disease-causing mutations are in these areas, rather than in the main protein-coding parts of genes themselves. Because these dif fer, particularly between species, this can make direct animal-human compari sons not just difficult and uncertain, but impossible (Bassett, 2017 ) . Even when humans and mice share genes, they can show functional differences: a study of 120 genes that are known to be essential for life in humans, revealed that almost one quarter of them are not essential for life in mice (Liao and Zhang, 2008) .
The problem with a shift toward GM NHPs, in the hope of greater human relevance, is that there is little or no evidence to support this, even if NHPs are evolutionarily less removed from humans. While it is true to some extent that N HPs "are genetically and phenotypically closer to humans, particularly in regards to anatomy, physiology, cognition, and gene sequences;' it does not fol low that they are, therefore, "optimal animal models for genetic modification in an attempt to understand human biology" (Luo et al., 2016, p. 241, ) . This is Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access only valid if this results in better translation of NHP data to human benefit. I argue that it does not, because there is simply no evidence that it does. One positive for animal advocates, while reading myriad literature on the burgeoning creation of GM animals, is that there now appears to be more hon esty about, and criticism of, the human relevance of non-GM animals. A paper in the prestigious journal, Nature, cited the wholesale failure of new drugs to treat amyotrophic lateral sclerosis (ALS ), a fatal neurodegenerative condition, known as Lou Gehrig's or motor neuron disease, despite success in animal models of the disease, as well as similar failures in Alzheimer's and cancer, among others (Perrin, 2014) . Contemporary criticisms of animal research are welcome because they have been scant from the scientific community for decades. Ironically, many criticisms are akin to those made by animal advocates for many years, which were roundly dismissed. What seems commonplace, however, is the unfortunate and groundless assertion that genetic modifica tion will instantly make failed animal models more human relevant. Evidence suggests otherwise.
7
Alternatives to GM Animals-The Way Forward
If not GM animals, what is the way forward to understand the myriad human diseases and realize treatments and cures for them? Modeling human diseases in cultured human stem cells continues to take great leaps forward and will surely become a mainstay of biomedical research that "could rival the use of GM mice in popularity" (Musunuru, 2013. p. 901) . Somatic cells ( cells from various parts of the body, other than reproductive cells, such as sperm and eggs, often skin biopsies or blood) can now be reprogrammed to act as cells in early-stage emb ry os, able to develop into many different specialized cell types (Takahashi et al., 2007; Takahashi and Ya manaka, 2006) . Immense collaborative efforts now collect and characterize cells from many thousands of healthy and dis eased human individuals, many with a wide variety of disorders, and use these induced pluripotent stem cells (iPscs) for comparative studies of normal and diseased states and screening of potential new drugs and therapies, including the study of polygenic disorders ( diseases involving many genes). The develop ment of 3D cell cultures and organoids ( cultured miniature organs) is likely to increase the in vivo relevance of this approach, with more faithful and accurate cellular phenotypes ( see Bassett, 2017 ) . Organoids successfully developed to date include, brain, intestine, stomach, salivary gland, esophagus, pancreas, liver, breast, lung, prostate, fallopian tube, and taste bud ( see Driehuis and Cle vers, 2017) . Genetically modifying such iPSCs and organoids adds another level of sophistication, allowing potential causative gene variants or mutations to be introduced for further stud y, for example, to validate mutations implicated in causing disease and/or for attempts at repairing faulty genes. Cell lines for these studies have been generated for many diseases, includ ing Parkinson's, Alzheimer's, Huntington disease, various immune disorders, cardiomyopathy, and cystic fibrosis (Brookhouser et al., 2017; Nishizaki and Boyle, 2017) ; and efforts at repairing mutated genes in these systems have been promising in, for example, cystic fibrosis and cancers (Driehuis and Clevers, 2017) , and retinopathies (Quinn, Pellissier and Wijnholds, 2017) . The combined use of genome editing and iPscs offers the ability to study genes and muta tions in different human genetic backgrounds, which is especially important for the study of complex neurological disorders. This approach has been found to "closely mimic cellular and molecular features of human diseases." (Heiden reich and Zhang, 2016 1 p. 42 ) CRISPR has also aided the derivation of retinal ganglion cells from human PS Cs, to model human optic nerves in vitro for re search into optic nerve disease (Sluch et al., 2015) . The very high efficiency of these types of methods, coupled with the relative ease and speed of the pro cess, and the ability to use and screen many thousands of cell lines in parallel, means that this type of approach to understanding the basis of human disease and to identify therapeutic targets and therapies must be the way forward, in place of creating GM animals (see Bassett, 2017) . While the aforementioned off-target effects are a confounding factor, they matter much less in cell lines than in animals, because there are no ethical problems; and cell lines can be produced, screened, and evaluated much more quickly and efficiently.
Summary
Acknowledgement of the suffering of GM animals has, at least, led to some efforts to reduce it, even if these have not, to date, led to overall reductions in their creation and experimental use. Guidelines for the use and care of GM animals, for example, are welcome. Working Groups and international guidelines have been commissioned to this end (Wells et al., 2006) and are at least intended to reduce the number of GM animals created and improve the welfare of those who are. These include requiring attempts to establish the appropriateness of generating any GM animal, both scientifically and with re gard to welfare, involving a harm-benefit analysis; and a stipulation that new animals should not be generated if similar suitable lines already exist, and/ or if an in vitro method could be used instead (Rose et al., 2013) . These guide lines need to be widely adopted and enforced, but also greater training of staff responsible for care, for example, can only make little or no impact on the welfare of the many millions of GM animals that will end up in laboratories worldwide. Ultimately, guidelines or not, GM animals suffer greatly, in their tens of millions each year. Controversially, one developing effort to address this, already attempted in rats, is to make GM animals who-while still able to sense pain-are incapable of finding its sensation unpleasant (Shriver, 2015) .
Ye t, the public demands that such pain and suffering is avoided or con trolled at all costs for them to accept animal research, GM or not (Aldhous et al., 1999; Animal Aid, 2003; Clemence and Leaman, 2016; Leaman, Latter and Clemence, 2014; TNS Opinion & Social, 2010 ) . Generally, people are much less accepting of GM animals than they are of GM plants and GM food compared to other GM applications. While perceptions of risk are offset by perceived ben efits (Prewer et al., 2013) , there is evidence that the EU populace has in the past "morally rejected genetic engineering of animal models of disease," which is incompatible with the direction in which worldwide attitudes and laws are moving (Rollin, 2015, p. 114) . Utilitarians may argue that human benefit out weighs this pain and suffering. But, given the degree of animal pain and suffer ing involved, both qualitatively and quantitatively, the relatively small number of people who stand to benefit from any breakthrough for many of the rare genetic diseases that may be modelled, and how unlikely GM animals are to contribute to breakthroughs given the burgeoning evidence against them, how can this be so? This is especially true if any harm-benefit analyses applied to license applications for animal experimentation are conducted properly and more stringently, as there are calls for authorities to ensure (Wiirbel, 2017 ) .
Even if one presumes sufficient human benefit from research on GM ani mals, which I ( and many others) believe is not supported by evidence, there remain serious scientific issues with, and ethical/welfare consequences of, genetic engineering. Despite the best currently available method of CRISPR having "swept through labs around the world" recently, and being touted as a "revolution" (Ledford, 2015, pp. 20-21) , it is still considered as being "in an im mature phase of development" and "not yet ready for therapeutic applications in humans given the low editing efficiency" ( <15%) (D'Agostino and D'Aniello, 2017, p. 4) . This is also due to the persistent concerns over the stubborn na ture of off-target mutations, occurring at frequencies of up to 60%, more than the best efficiency of intended on-target modifications. Even if off-target is sues can be greatly reduced, which is questionable, they are still of concern clinicall y, as "Even low-frequency events could potentially be dangerous if they accelerate a cell's growth and lead to cancer" (Ledford, 2015, p. 22 ) . Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access
The efficiency of CRISPR translation to clinical applications is also of con cern. Scientists using CRISPR to correct a disease-causing mutation in mice in a gene therapy experiment had to "pump large volumes of liquid into blood vessels-something that is not generally considered feasible in people" and this corrected the mutation in just 0-4°/o of the mice's cells, not enough to be effective (Ledford, 2015, p. 21) . Delivery methods for introducing the CRISPR apparatus to cells also need optimizing (Peng, Lin and Li, 2016) . Carrier DNA used to introduce CRISPR to target cells may become integrated into the host genome, causing off-target effects, which may disrupt the genome editing pro cess and can cause toxicity. Alternative methods may be stressful to cells, alter ing gene expression, or leading to high off-target effects (Peng, Lin and Li, 2016) . Despite these concerns, the first clinical trial involving CRISPR commenced in October 2016, when knockout immune cells were injected into patients as po tential therapy for metastatic non-small cell lung cancer (Cyranoski, 2016a) ; and now CRISPR is already part of ten clinical trials just a few years after it became mainstream ( clinicaltrials.gov). It remains to be seen if they will be successful, and if so, how much they rely on GM animal research.
g Conclusion
GM animal creation and experimentation takes the lives of tens of millions of animals each year and involves considerable suffering at every stage. Its sci entific value is extremely poor, to the point of it being unnecessary, mislead ing and therefore harmful not just to the animals involved, but also to people, who depend on good science to understand, treat, and cure the diseases that affect us all. The continued insistence of many who practice and fund GM re search that animals must be used is without foundation. Non-human animals have always been bad models for humans due to species differences, and no amount of genetic modification can remedy that, even if it were perfect. GM processes are far from perfect, however. Even the best is extremely inefficient, and confounded not just by those species differences, but also by off-target effects of the GM process. These issues are at the root of animal research fail ing to be relevant and reliable for humans, of animals being poor models for disease right across the spectrum, and of the failure of 90%-95% of new drugs in human trials that were successful in animal tests (Bailey, Thew and Balls, 2013; Bailey, Thew and Balls, 2014; Bailey, Thew and Balls, 2015) . Moving away from animal research, including the use of GM animals, has never been more imperative.
